In terms of molecular subtypes, significantly better overall survival for patients with HR-positive breast cancer may be attributed to safe and effective endocrine therapy, while the advent of several HER2-targeted therapies also has significantly reversed inferior survival outcomes of HER2-positive breast cancer, making the median survival of advanced HER2-positive breast cancer now approach 5 years (18). The gene discussed is ERBB2; the disease is breast carcinoma.